Oncology Brothers: Practice-Changing Cancer Discussions

Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study.
We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients.
Key topics covered in this episode included:• Overview of the Keynote-905/EV-303 study and its significance• Comparison with previous studies like the NIAGARA trial• Discussion on the side effects of EV Pembro and management strategies• The role of ctDNA in guiding post-operative therapy• Future directions in bladder cancer research and upcoming trials
Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology!#BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo

Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer.Join us as we discussed:• The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies• Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials• A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant diseaseWe were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies.
Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!
#SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE

In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.
Join us as we dive into three key abstracts:1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy.3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status).
We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward.
Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer!
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights.
#SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC

Advancements and Challenges in Metastatic Colorectal Cancer Treatment

In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi.
Key topics included:* The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning.* An overview of second-line treatment options such as Tas-102 with Bevacizumab, Regorafenib, and Fruquintinib, along with their respective clinical trial data.* Insights into side effect management and quality of life considerations for patients undergoing palliative treatment.* A discussion on the recent STELLAR-303 study and its implications for immunotherapy in colorectal cancer.
Join us as we bridge the gap between academia and community practice, emphasizing the need for improved treatment options and patient care in the realm of refractory colorectal cancer.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing updates!
#ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology

Clinical Implications of Testing HER2 and Targeted Therapies Approved - Dr. Komal Jhaveri

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.
Key topics include:• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.• The definition and implications of low and ultra-low HER2 expression in clinical practice.• The importance of HER2 testing and the dynamic nature of HER2 expression in tumors.• Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan.• Management of treatment-related toxicities, including ILD, nausea, and alopecia.
Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and insights!

Toxicity Management of HER2+ Treatment Options in Upper GI Cancers – Drs. Geoffrey Ku & Shruti Patel

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University.
Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists.
Episode Highlights:• Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab• Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer• Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers• Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies• TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management• Expert consensus on infusion reaction management for novel biologics• The importance of managing baseline symptoms in patients with dysphagia and nausea
This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies!
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease.
Episode Highlights:• Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings.• Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options.• Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status.• The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions.• Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape.• Considerations for managing side effects and the importance of treatment sequencing in palliative care.
Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights!
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications 
 
#HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V).
We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education.
Key topics covered in this episode:• Overview of ADCs and their role in NSCLC treatment• TDXd: alopecia, ILD, fatigue, nausea/vomiting• Dato-DXd:  cytopenias, mucositis, dry eyes• Teliso-V: peripheral neuropathy, fatigue, peripheral edema• The evolving landscape of ADCs and future directions in lung cancer treatment
Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology!
#ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

Managing Toxicities of PI3K & AKT Inhibitors in Breast Cancer – Drs. Emily Gallagher & Neil Iyengar

Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer.
We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and gastrointestinal issues. Our experts shared practical management strategies, dosing considerations, and the importance of patient education to ensure safe and effective treatment.
Key topics covered in this episode:• Overview of PIK3CA and AKT inhibitors• Common side effects and their management• The significance of proactive patient education• Dosing strategies and when to consider dose modifications• Insights on managing hyperglycemia and gastrointestinal symptoms
This episode is packed with valuable information to enhance your understanding of these important therapies in the breast cancer world. Don't forget to subscribe for more episodes on treatment algorithms, toxicities, and the latest in oncology!
#PI3Kinhibitors #BreastCancer #Hyperglycemia #ToxCheck #MetastaticBC #OncologyBrothers #TargetedTherapy

Challenging Cases of Iron Abnormalities, Anemia or Iron Overload - Dr. Marina Beltrami

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:
1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral iron.2. Anemia with Mixed Etiologies: We analyzed a case involving a 78-year-old man with a history of prostate cancer, diabetes, and chronic kidney disease, discussing the broad differential diagnosis and the role of bone marrow biopsy and molecular studies.3. Iron Overload: We examined a 47-year-old woman with elevated ferritin levels and a heterozygous hemochromatosis mutation, debating the necessity of phlebotomy and the importance of liver imaging.
Throughout the episode, we emphasized the significance of a comprehensive iron panel and the clinical context in diagnosing and managing these conditions. Dr. Beltrami shared valuable insights on the use of erythropoietin-stimulating agents in chronic kidney disease and the potential risks associated with their use.
Tune in for an informative discussion packed with practical insights for healthcare professionals dealing with iron-related disorders!
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. We are the Oncology Brothers!
#Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers